In summary, these findings suggest that TSPAN8 is a promising therapeutic target for radioimmunotherapy in a broad range of TSPAN8-expressing cancers, including melanoma, glioma, hepatocellular carcinoma, ovarian and gastric cancers as well as aggressive CRC tumors [95]. Here, TSPAN8 is linked to melanoma.